118 related articles for article (PubMed ID: 31203267)
21. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
22. The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer.
Grimaldi F; Valotto C; Barbina G; Visentini D; Trianni A; Cerruto MA; Zattoni F
Int J Biol Markers; 2006; 21(4):229-34. PubMed ID: 17177161
[TBL] [Abstract][Full Text] [Related]
23. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
24. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Stamey TA; Kabalin JN; McNeal JE; Johnstone IM; Freiha F; Redwine EA; Yang N
J Urol; 1989 May; 141(5):1076-83. PubMed ID: 2468795
[TBL] [Abstract][Full Text] [Related]
25. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.
Isshiki S; Akakura K; Komiya A; Suzuki H; Kamiya N; Ito H
J Urol; 2002 Feb; 167(2 Pt 1):512-5. PubMed ID: 11792908
[TBL] [Abstract][Full Text] [Related]
26. Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival.
Niedworok C; Tschirdewahn S; Reis H; Lehmann N; Szücs M; Nyirády P; Romics I; Rübben H; Szarvas T
Pathol Oncol Res; 2017 Jul; 23(3):643-650. PubMed ID: 28012116
[TBL] [Abstract][Full Text] [Related]
27. Association between serum levels of insulin-like growth factor-1, bioavailable testosterone, and pathologic Gleason score.
Kim M; Kim JW; Kim JK; Lee SM; Song C; Jeong IG; Hong JH; Kim CS; Ahn H
Cancer Med; 2018 Aug; 7(8):4170-4180. PubMed ID: 29992746
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
29. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
30. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
31. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
32. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
[TBL] [Abstract][Full Text] [Related]
33. Serum chromogranin-A in advanced prostate cancer.
Ferrero-Poüs M; Hersant AM; Pecking A; Brésard-Leroy M; Pichon MF
BJU Int; 2001 Nov; 88(7):790-6. PubMed ID: 11890255
[TBL] [Abstract][Full Text] [Related]
34. Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer.
Reis LO; Vieira LF; Zani EL; Denardi F; de Oliveira LC; Ferreira U
J Investig Med; 2010 Dec; 58(8):957-60. PubMed ID: 20818262
[TBL] [Abstract][Full Text] [Related]
35. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer.
Schnoeller T; Jentzmik F; Rinnab L; Cronauer MV; Damjanoski I; Zengerling F; Ghazal AA; Schrader M; Schrader AJ
World J Urol; 2013 Apr; 31(2):253-9. PubMed ID: 22763628
[TBL] [Abstract][Full Text] [Related]
36. Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy.
Krauss DJ; Amin M; Stone B; Ye H; Hayek S; Cotant M; Hafron J; Brabbins DS
Prostate; 2014 May; 74(5):520-7. PubMed ID: 24375481
[TBL] [Abstract][Full Text] [Related]
37. Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.
Pichon A; Neuzillet Y; Botto H; Raynaud JP; Radulescu C; Molinié V; Herve JM; Lebret T
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):382-7. PubMed ID: 26439747
[TBL] [Abstract][Full Text] [Related]
38. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature.
D'Angelillo RM; Greco C; Fiore M; Ippolito E; Eolo Trodella L; Iurato A; Molfese E; Ramella S; Trodella L
Tumori; 2014; 100(3):249-53. PubMed ID: 25076233
[TBL] [Abstract][Full Text] [Related]
40. Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience.
Singh P; Dogra PN; Gupta NP; Nayyar R; Seth A; Javali TD; Kumar R
Indian J Cancer; 2011; 48(4):483-7. PubMed ID: 22293265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]